Display options
Cite
Vayssettes-Courchay C, Melka J, Philouze C, et al. Sympathetic Nerve Activity and Baroreflex are Strongly Altered in a Context of Severe Hypertension Using the Spontaneously Hypertensive Rat Model Associated with Chronic Reduction of Nitric Oxide. Int J Hypertens. 2021;2021:4808657doi: 10.1155/2021/4808657.
Vayssettes-Courchay, C., Melka, J., Philouze, C., & Harouki, N. (2021). Sympathetic Nerve Activity and Baroreflex are Strongly Altered in a Context of Severe Hypertension Using the Spontaneously Hypertensive Rat Model Associated with Chronic Reduction of Nitric Oxide. International journal of hypertension, 20214808657. https://doi.org/10.1155/2021/4808657
Vayssettes-Courchay, Christine, et al. "Sympathetic Nerve Activity and Baroreflex are Strongly Altered in a Context of Severe Hypertension Using the Spontaneously Hypertensive Rat Model Associated with Chronic Reduction of Nitric Oxide." International journal of hypertension vol. 2021 (2021): 4808657. doi: https://doi.org/10.1155/2021/4808657
Vayssettes-Courchay C, Melka J, Philouze C, Harouki N. Sympathetic Nerve Activity and Baroreflex are Strongly Altered in a Context of Severe Hypertension Using the Spontaneously Hypertensive Rat Model Associated with Chronic Reduction of Nitric Oxide. Int J Hypertens. 2021 Nov 25;2021:4808657. doi: 10.1155/2021/4808657. eCollection 2021. PMID: 34868673; PMCID: PMC8639277.
Copy Download .nbib Format: NLM
Share it on

Int J Hypertens. 2021 Nov 25;2021:4808657. doi: 10.1155/2021/4808657. eCollection 2021.

Sympathetic Nerve Activity and Baroreflex are Strongly Altered in a Context of Severe Hypertension Using the Spontaneously Hypertensive Rat Model Associated with Chronic Reduction of Nitric Oxide.

International journal of hypertension

Christine Vayssettes-Courchay, Jonathan Melka, Clothilde Philouze, Najah Harouki

Affiliations

  1. Servier Research Institute, 11 Rue des Moulineaux, Suresnes 92150, France.

PMID: 34868673 PMCID: PMC8639277 DOI: 10.1155/2021/4808657

Abstract

The aim of our study is to investigate the sympathetic output and baroreflex via renal sympathetic nerve activity (RSNA) recording in a model of severe hypertension which exhibits arterial, cardiac, and renal damages, the spontaneously hypertensive rat (SHR) under lowered NO bioavailability. SHR are treated from 18 to 20 weeks of age with a low dose of L-NAME, a NO synthase inhibitor, in drinking water (SHRLN) and compared to SHR and normotensive Wistar Kyoto (WKY) rats. After the two-week treatment, rats are anesthetized for RSNA, mean blood pressure (MBP), and heart rate (HR) recording. MBP is higher in SHR than in WKY and higher in SHRLN than in SHR. Compared to WKY, SHR displays an alteration in the baroreflex with a displacement of the sympathoinhibition curve to highest pressures; this displacement is greater in SHRLN rats. The bradycardic response is reduced in SHRLN compared to both SHR and WKY. In hypertensive rats, SHR and SHRLN, basal RSNA is modified, the maximal amplitude of burst is reduced, but minimal values are increased, indicating an increased basal RSNA with reduced bursting activity. The temporal correlation between RSNA and HR is preserved in SHR but altered in 10 SHRLN out of 10. The RSNA inhibition triggered by the Bezold-Jarisch reflex activation is not modified in hypertensive rats, SHR or SHRLN, in contrast to that triggered by the baroreflex. Histological analysis of the carotid bifurcation does not reveal any abnormality in SHRLN at the level of the carotid sinus. In conclusion, data indicate that the sympathetic outflow is altered in SHRLN with a strong reduction of the baroreflex sympathoinhibition and suggest that its central pathway is not involved. These additional results on SHRLN also confirm the usefulness of this model of severe hypertension with multiple target organ damages.

Copyright © 2021 Christine Vayssettes-Courchay et al.

Conflict of interest statement

The authors declare that they have no conflicts of interest.

References

  1. Clin Exp Pharmacol Physiol Suppl. 1989;15:85-7 - PubMed
  2. Hypertension. 2005 Jul;46(1):227-31 - PubMed
  3. J Hypertens. 2004 Jul;22(7):1389-95 - PubMed
  4. Physiol Rev. 2010 Apr;90(2):513-57 - PubMed
  5. Clin Exp Pharmacol Physiol. 1992 Aug;19(8):587-97 - PubMed
  6. Med Chem. 2007 Jan;3(1):61-5 - PubMed
  7. Am J Physiol Heart Circ Physiol. 2011 Aug;301(2):H382-90 - PubMed
  8. J Auton Nerv Syst. 1984 Sep;11(2):115-24 - PubMed
  9. Int J Hypertens. 2019 Mar 19;2019:8070198 - PubMed
  10. J Hypertens. 2020 Jun;38(6):982-1004 - PubMed
  11. J Cardiovasc Pharmacol. 2002 Nov;40(5):789-800 - PubMed
  12. Br J Anaesth. 2001 Jun;86(6):859-68 - PubMed
  13. J Vasc Res. 2012;49(4):309-18 - PubMed
  14. Curr Hypertens Rep. 2018 Sep 7;20(11):92 - PubMed
  15. Auton Neurosci. 2005 Jun 15;120(1-2):35-45 - PubMed
  16. Brain Res. 1997 Jan 9;744(2):272-8 - PubMed
  17. Am J Physiol Heart Circ Physiol. 2003 Oct;285(4):H1363-9 - PubMed
  18. Nat Rev Neurosci. 2006 May;7(5):335-46 - PubMed
  19. Anesthesiology. 2003 May;98(5):1250-60 - PubMed
  20. Br J Pharmacol. 2012 Oct;167(4):854-67 - PubMed
  21. J Hypertens. 2016 Apr;34(4):666-75 - PubMed
  22. Can J Cardiol. 2020 May;36(5):712-720 - PubMed
  23. Hypertension. 1995 Aug;26(2):249-55 - PubMed
  24. Kardiol Pol. 2019;77(2):71-159 - PubMed
  25. Hypertension. 1999 Oct;34(4 Pt 1):609-16 - PubMed
  26. Am J Physiol. 1992 Dec;263(6 Pt 2):R1195-202 - PubMed

Publication Types